DC
ORIC icon

Diametric Capital’s Oric Pharmaceuticals ORIC Stock Holding History

Diametric Capital’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,127
Closed -$74.8K – 432
2023
Q1 		$74.8K Buy
+13,127
New +$68.6K 0.04% 287

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Diametric Capital's ORIC Position: Q2 2023 in Review

Diametric Capital sold out of Oric Pharmaceuticals (ORIC) in Q2 2023, closing a stake of 13,127 shares — an estimated $74.8K sold.

Diametric Capital first reported a position in ORIC in Q1 2023 and held it in 1 quarter. The position peaked at $74.8K in Q1 2023. 83 funds tracked by Wall St. Rank hold ORIC as of Q2 2023.

  • Diametric Capital reported no remaining Oric Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Diametric Capital sold 13,127 Oric Pharmaceuticals shares in Q2 2023, an estimated $74.8K.
  • Diametric Capital first reported a position in Oric Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Diametric Capital's Oric Pharmaceuticals position peaked at $74.8K in Q1 2023.
  • 83 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2023.

Based on Diametric Capital's 13F filing for Q2 2023, filed 11 Aug 2023.